VentriPoint DiagnosticsVPTDF -1.60%10 EBIT per Share is $-0.01 as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks better than 54.2% on this metric.
VentriPoint Diagnostics's EBIT per Share for the
three
months ended in Dec. 2025 was $0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.01.
During the past 3 years, the average EBIT per Share Growth Rate was 12.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -0.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 13.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for VentriPoint Diagnostics's EBIT per Share or its related term are showing as below:
VPTDF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -129.9 Med: 15.5 Max: 39.8
Current: 12.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of VentriPoint Diagnostics was 39.80% per year. The lowest was -129.90% per year. And the median was 15.50% per year.
VPTDF's 3-Year EBIT Growth Rate is ranked better than 54.2% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs VPTDF: 12.20
VentriPoint Diagnostics (OTCPK:VPTDF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
VentriPoint Diagnostics EBIT per Share Related Terms
VentriPoint Diagnostics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a EBIT per Share of $-0.01 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #316 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 45.8%.
Is VentriPoint Diagnostics' EBIT per Share too high?
VentriPoint Diagnostics' current EBIT per Share is $-0.01. Based on the distribution chart, VentriPoint Diagnostics ranks #316 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, VentriPoint Diagnostics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #316 out of 690 companies for EBIT per Share. This puts VentriPoint Diagnostics in the upper half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current EBIT per Share is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current EBIT per Share of $-0.01. The current EBIT per Share is $-0.01. VentriPoint Diagnostics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current EBIT per Share is $-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
10GF Score
Get the complete analysis for VPTDF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
